Hansa, Biopharma

Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome

Veröffentlicht: 07.08.2025 um 18:08 Uhr, prnewswire.co.uk

Hansa Biopharma AB Sweden New York

View original content:https://www.prnewswire.co.uk/news-releases/hansa-biopharma-announces-positive-full-results-from-15-hmedides-09-phase-2-study-and-comparative-analysis-of-imlifidase-in-patients-with-guillain-barre-syndrome-302334285.html

en | boerse | 67927961 |